Adial Pharmaceuticals, Inc.

ADIL · NASDAQ

ADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.

Follow Add to Watchlist Ask Question

NASDAQ ADIL Coverage Bootstrap Biotechnology Addiction Medicine Alcohol Use Disorder

Latest ReportMay 14, 2026Adial Pharmaceuticals: the cheek-swab alcohol-use pill racing a 2026 runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.